Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

(2021) Allison J. Greaney et al.   Cell Host & Microbe

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

(2021) Kai Wu et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

(2021) Markus Hoffmann et al.   CELL

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

(2021) Xianding Deng et al.   CELL

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

(2021) Katherine R W Emary et al.   LANCET

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

(2021) Vivek Shinde et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates

(2021) Kizzmekia S. Corbett et al.   NATURE IMMUNOLOGY

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

(2021) Talia Kustin et al.   NATURE MEDICINE

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

(2021) Angela Choi et al.   NATURE MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies

(2021) Hao Zhou et al.   mBio

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

(2021) Takuya Tada et al.   mBio

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

(2020) Michael Letko et al.   Nature Microbiology

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

(2020) Qihui Wang et al.   CELL

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

Cell entry mechanisms of SARS-CoV-2

(2020) Jian Shang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

(2020) Bette Korber et al.   CELL

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

(2020) Kizzmekia S. Corbett et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of mRNA chemistry and manufacturing process on innate immune activation

(2020) Jennifer Nelson et al.   Science Advances

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

(2020) Leonid Yurkovetskiy et al.   CELL

Spike mutation D614G alters SARS-CoV-2 fitness

(2020) Jessica A. Plante et al.   NATURE

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines

(2019) Kimberly J. Hassett et al.   Molecular Therapy-Nucleic Acids

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

(2018) Annette B. Vogel et al.   MOLECULAR THERAPY

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity

(2018) Shinu John et al.   VACCINE

Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

(2017) Kapil Bahl et al.   MOLECULAR THERAPY

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

(2010) Michael A. Whitt   JOURNAL OF VIROLOGICAL METHODS